CoChat

B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination

Open access
Arora, Prerna, Sidarovich, Anzhalika, Krüger, Nadine, Kempf, Amy, Nehlmeier, Inga, Graichen, Luise, Moldenhauer, Anna-Sophie, Winkler, Martin S., Schulz, Sebastian, Jäck, Hans-Martin, Stankov, Metodi V., Behrens, Georg M.N., Pöhlmann, Stefan, Hoffmann, Markus · 2021 · Cell Reports
Cited by 76

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

The Delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), B.1.617.2, emerged in India and has spread to over 80 countries. B.1.617.2 replaced B.1.1.7 as the dominant virus in the United Kingdom, resulting in a steep increase in new infections, and a similar development is expected for other countries. Effective countermeasures require information on susceptibility of B.1.617.2 to control by antibodies elicited by vaccines and used for coronavirus disease 2019 (COVID-19) therapy. We show, using pseudotyping, that B.1.617.2 evades control by antibodies induced upon infection and BNT162b2 vaccination, although to a lesser extent as compared to B.1.351. We find that B.1.617.2 is resistant against bamlanivimab, a monoclonal antibody with emergency use authorization for COVID-19 therapy. Finally, we show increased Calu-3 lung cell entry and enhanced cell-to-cell fusion of B.1.617.2, which may contribute to augmented transmissibility and pathogenicity of this variant. These results identify B.1.617.2 as an immune evasion variant with increased capacity to enter and fuse lung cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.celrep.2021.109825

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 13

  1. Bussani, 2020, Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology, EBioMedicine, 61, 103104, 10.1016/j.ebiom.2020.103104 · DOI · Paper page
  2. Campbell, 2021, Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021, Euro Surveill., 26, 2100509, 10.2807/1560-7917.ES.2021.26.24.2100509 · DOI · Paper page
  3. Golob, 2021, SARS-CoV-2 vaccines: a triumph of science and collaboration, JCI Insight, 6, e149187, 10.1172/jci.insight.149187 · DOI
  4. Hoffmann, 2020, SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell, 181, 271, 10.1016/j.cell.2020.02.052 · DOI · Paper page
  5. Jones, 2020, LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection, bioRxiv
  6. Liu, 2021, BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants, Nature, 596, 273, 10.1038/s41586-021-03693-y · DOI · Paper page
  7. Plante, 2021, The variant gambit: COVID-19's next move, Cell Host Microbe, 29, 508, 10.1016/j.chom.2021.02.020 · DOI · Paper page
  8. Singh, 2021, SARS-CoV-2 variants of concern are emerging in India, Nat. Med., 27, 1131, 10.1038/s41591-021-01397-4 · DOI · Paper page
  9. Suryadevara, 2021, Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein, Cell, 184, 2316, 10.1016/j.cell.2021.03.029 · DOI · Paper page
  10. Tian, 2020, Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer, J. Thorac. Oncol., 15, 700, 10.1016/j.jtho.2020.02.010 · DOI · Paper page
  11. Wang, 2021, Vaccine-escape and fast-growing mutations in the United Kingdom, the United States, Singapore, Spain, India, and other COVID-19-devastated countries, Genomics, 113, 2158, 10.1016/j.ygeno.2021.05.006 · DOI · Paper page
  12. Xia, 2021, Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial, Lancet Infect. Dis., 21, 39, 10.1016/S1473-3099(20)30831-8 · DOI · Paper page
  13. Xu, 2020, Pathological findings of COVID-19 associated with acute respiratory distress syndrome, Lancet Respir. Med., 8, 420, 10.1016/S2213-2600(20)30076-X · DOI · Paper page

Cited by

See all 76

Metadata

Authors
Arora, P., Sidarovich, A., Krüger, N., Kempf, A., Nehlmeier, I., Graichen, L., Moldenhauer, A.-S., Winkler, M. S., Schulz, S., Jäck, H.-M., Stankov, M. V., Behrens, G. M. N., Pöhlmann, S., & Hoffmann, M.
Venue
Cell Reports
Publisher
Elsevier BV
Published
2021-10
Volume
37
Issue
2
Pages
109825
ISSN
2211-1247 (ISSN-L)
OpenAlex
W3202256154
Cited by
76
References
19
FWCI
5.11
Type
journal article
Language
en
Open access
gold
Licence
Funders
  • Deutsche Forschungsgemeinschaft (01KI2074A, PO 716/11-1, PO 716/14-1, RTG1660, TRR130)
  • Bundesministerium für Bildung und Forschung (01KI2006D, 01KI20328A, 01KI20396, 01KX2021)
  • Bundesministerium fur Bildung und Forschung Dienststelle Berlin (01KI2043)
  • Niedersächsisches Ministerium für Wissenschaft und Kultur (14-76103-184, MWK HZI COVID-19)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.